报价延迟最少15分钟:2026/04/15 09:41 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.34 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.90/-0.18
|
|
企业价值
830.64M
|
| 资产负债 |
|
每股账面净值
1.45
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
185.74M
|
|
每股收益
3.72
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services. |
